J. Goldman & Co LP purchased a new stake in Celcuity Inc. (NASDAQ:CELC - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 43,345 shares of the company's stock, valued at approximately $567,000. J. Goldman & Co LP owned 0.12% of Celcuity as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Summit Investment Advisors Inc. grew its stake in shares of Celcuity by 49.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after buying an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Celcuity in the 4th quarter worth approximately $50,000. The Manufacturers Life Insurance Company acquired a new position in shares of Celcuity in the 4th quarter worth approximately $142,000. Bleakley Financial Group LLC acquired a new position in shares of Celcuity in the 4th quarter worth approximately $146,000. Finally, Trexquant Investment LP bought a new position in Celcuity during the 4th quarter worth $152,000. Institutional investors and hedge funds own 63.33% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on CELC shares. Needham & Company LLC restated a "buy" rating and set a $29.00 price objective on shares of Celcuity in a research note on Thursday. HC Wainwright reiterated a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research report on Tuesday, April 1st. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $30.17.
Get Our Latest Analysis on Celcuity
Celcuity Stock Down 3.1%
NASDAQ:CELC traded down $0.34 during trading hours on Thursday, hitting $10.52. 170,391 shares of the company's stock traded hands, compared to its average volume of 298,574. The firm has a market cap of $398.07 million, a P/E ratio of -4.03 and a beta of 0.56. Celcuity Inc. has a twelve month low of $7.58 and a twelve month high of $19.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The stock's fifty day moving average price is $10.14 and its two-hundred day moving average price is $11.77.
Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.09. On average, research analysts expect that Celcuity Inc. will post -2.62 earnings per share for the current fiscal year.
Celcuity Profile
(
Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Further Reading
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
